ReviewCurrent obesity reports2025
Harnessing Adipose Ferroptosis: A Promising Novel Pathway for Obesity Treatment.
Review in Current obesity reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Repurposing approved drugs as ferroptosis modulators: a critical review of clinical trials in cancer and neurodegeneration.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purpose of reviewThis review summarizes the potential of targeting ferroptosis-iron-dependent lipid peroxidation-as a novel strategy for treating obesity and its metabolic complications through mechanisms different from traditional interventions. RECENT
findingsRecent preclinical studies show that selectively inducing ferroptosis in lipid-rich adipocytes and obese mice can effectively decrease fat mass and enhance metabolic health. These ferroptosis-based methods target the fundamental cellular processes of adipocyte dysfunction, affecting lipid metabolism and reducing oxidative stress. The strategy appears promising in addressing major metabolic issues such as insulin resistance and hepatic steatosis. In addition, the ability to customize ferroptosis inducers based on individual metabolic profiles offers a pathway to highly personalized obesity treatments. Ferroptosis agonists offer a revolutionary therapeutic approach for obesity treatment by directly reducing fat mass and targeting key metabolic issues. However, applying these findings in clinical settings requires careful evaluation of the long-term safety and effects of pharmacological ferroptosis induction. This review highlights important gaps in current knowledge and suggests future research directions crucial for developing these innovative therapies.
Indexed as
Identifiers
41137986What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.